Gemcitabine and carboplatin: Is this the bes combination for non-small cell lung cancer?

Expert Review of Anticancer Therapy

Volumn 6, Issue 2, 2006, Pages 165-173

  Saha, Antonio ^a   Rudd, Robin ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Cost analyses; Gemcitabine carboplatin doublet; Median survival; Non small cell lung cancer; Out patient setting; Overall survival; Palliation; Progression free survival; Quality of life; Third generation cytotoxics; Toxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; VINCA ALKALOID; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ALOPECIA; ANAPHYLAXIS; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EDEMA; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; META ANALYSIS; METASTASIS; MULTIMODALITY CANCER THERAPY; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OUTPATIENT CARE; PARALYTIC ILEUS; PHARMACODYNAMICS; PROGNOSIS; PROTEINURIA; PRURITUS; QUALITY OF LIFE; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VOMITING; ECONOMICS; LUNG TUMOR; REVIEW; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; HUMANS; LUNG NEOPLASMS; PROGNOSIS; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 33644871922     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.2.165     Document Type: Article

References (55)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
2. Toms JR. CancerStats Monograph 2004. Cancer Research, London, UK. 45-54 (2004).
3. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 123(Suppl. 1), S21-S49 (2003).
4. Bailey-Wilson JE, Amos CI, Pinney SM et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am. J. Hum. Gene 75(3), 460-74 (2004).
5. Harvey JC, Erdman C, Pisch J. Surgical treatment of non-small cell lung cancer in patients older than seventy years. J. Surg. Oncol. 60 247-249 (1995).
6. Firat S, Bousamra M, Gore E, Byhardt RW. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 52(4), 1047-1057 (2002).
7. Carney DN, Hansen HH. Non-small-cell lung cancer-stalemate or progress? N. Engl. J. Med. 343 126, 1-2 (2000).
8. Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 350(9072), 161-165 (1997).
9. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer database report. Cancer 86(9), 1867-1876 (1999).
10. National Collaborating Centre for Acute Care. Lung cancer: the diagnosis and treatment of lung cancer. Clinical Guideline 24. National Institute for Clinical Excellence. London, UK. (2005).
11. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J. 311 899-909 (1995).
12. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 17, 1748-1756 (1989).
13. Bonomi PD, Finkelstein DM, Ruckdeschel JC et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 7, 1602-1613 (1989).
14. Klastersky J, Sculier JP, Lacroix H et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J. Clin. Oncol. 8(9), 1556-62 (1990).
15. Natale RB. Overview of current and future chemotherapeutic agents in non-small cell lung cancer. Semin. Oncol. 24(2 Suppl. 7), S7-S29, S7-S37 (1997).
16. Bunn PA Jr. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J. Clin. Oncol. 20(Suppl. 18), S23-S33 (2002).
17. Hertel LW, Kroin JS, Misner JW, Tustin JM. Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2′-difluoro-D-ribofuranosyl nucleosides. J. Org. Chem. 53(11), 2406-2409 (1988).
18. In: Physician's Desk Reference. Thomson Healthcare Products. Electronic Library Version 7.0.308a, (2005)
19. Thatcher N, Jayson G, Bradley B, Ranson M, Anderson H. Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer. Semin. Oncol. 24(3 Suppl.8), S8-S6-S8-S12 (1997).
20. Anderson H, Hopwood P, Stephens RJ et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br. J. Cancer 83(4), 447-453 (2000).
21. Abbruzzese JL, Grunewald R, Weeks EA et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J. Clin. Oncol. 9, 491-498 (1991).
22. Fosella FV, Lippman S, Pang A et al. Phase I/II study of gemcitabine by 30 minute weekly intravenous infusion × 3 weeks every 4 weeks for non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 12, 326 (1993).
23. Abratt RP, Bezwoda WR, Falkson G, Goedhals L Hacking, D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J. Clin. Oncol. 12, 1535-1540 (1994).
24. Gatzemeier U, Shepherd FA, Le Chevalier T et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur. J. Cancer 32A(2), 243-248 (1996).
25. Carmichael J, Allerheiligen S, Walling J. A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. Semin. Oncol. 23(5Suppl. 10), 55-59 (1996).
26. Parente B, Barroso A, Conde S, Guimarães T, Seada J. A prospective study of gemcitabine and carboplatin as first-line therapy in advanced non-small cell lung cancer: toxicity of a three- versus a four-week schedule. Semin. Oncol. 28(Suppl.10), 10-14 (2001).
27. Sederholm C. Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLUSG). Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 1162).
28. Cullen MH, Billingham LJ, Woodroffe CM et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J. Clin. Oncol. 17(10), 3188-3194 (1999)
29. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C303. A quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85, 365-376 (1993).
30. Bergman B, Aaronson NK, Ahmedzai S Kaasa S, Sullivan M. The EORTC QLQ-LC13. A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur. J. Cancer 30A, 635-642 (1994).
31. Gower NH, Rudd RM, Ruiz de Elvira MC et al. Assessment of 'quality of life' using a daily diary card in a randomized trial of chemotherapy in small-cell lung cancer. Ann. Oncol. 6, 575-580 (1995).
32. Rudd RM, Gower NH, Spiro SG et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J. Clin. Oncol. 23, 142-153 (2005).
33. Le Chevalier T, Scagliotti G, Natale R et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47(1), 69-80 (2005).
34. Zatloukal P, Petruzelka L, Zemanova M et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 41(3), 321-31 (2003).
35. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346, 92-98 (2002).
36. Crino L, Scagliotti G, Marangolo M et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J. Clin. Oncol. 15(1), 297-303 (1997).
37. Mazzanti P, Massacesi C, Rocchi MB et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 41(1), 81-89 (2003).
38. Iaffaioli RV, Tortoriello A, Facchini G et al. Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. J. Clin. Oncol. 17(3), 921-926 (1999).
39. Alberola V, Camps C, Provencia M et al. Cisplatin/Gemcitabine (CG) vs Cisplatin/Gemcitabine/Vinorelbine (CGV) vs Sequential Doublets of Gemcitabine/ Vinorelbine Followed by Ifosfamide/ Vinorelbine (GV/IV) in Advanced Non-Small Cell Lung Cancer (NSCLC): Results of a Spanish Lung Cancer Group Phase III Trial (GEPC/9, 8-02). Proc. Am. Soc. Clin. Oncol. 20, 308a (2001) (Abstract 1229).
40. Edelman MJ, Clark JI, Chansky K et al. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/ vinorelbine followed by docetaxel. Clin. Cancer Res. 10(15), 5022-5026 (2004).
41. Shepherd F, Pereira J, Ciuleanu TE et al. Erlotinib in previously treated non-small cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005).
42. Gatzemeier UPA, Szczesna A et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 22(Suppl. 14) (2004) (Abstract 7010).
43. Novello S, Kielhorn A, Stynes G et al. Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/ cisplatin in the treatment of advanced non-small cell lung cancer in Italy. Lung Cancer 48(3), 379-387 (2005).
44. Schiller J, Tilden D, Aristides M et al. Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer 43(1), 101-112 (2004).
45. Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J. Clin. Oncol. 17(9), 2692-2699 (1999).
46. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer. A meta-analysis. Cancer 76(4), 593-601 (1995).
47. Scalliet P, Goor C, Galdermans D et al. Gemcitabine with thoracic radiotherapy - A Phase II pilot study in chemonaive patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 17, 499 (Abstract 1923) (1998).
48. Price A, Groen H, Gregor A et al. A phase I study of weekly gemcitabine as a radiosensitiser in stage III non-small cell lung cancer. Lung Cancer 29(Suppl. 1), 105 (2000).
49. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 352(9124), 257-263 (1998).
50. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med. 352(25), 2589-2597 (2005).
51. Strauss GM, Herndon J, Maddaus MA et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. Proc. Am. Soc. Clin. Oncol. 22(Suppl. 1), 621S (Abstract 7019) (2004).
52. Depierre A, Milleron B, Moro-Sibilot D et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J. Clin. Oncol. 20(1), 247-253 (2002).
53. Maestu I, Gomez-Aldaravi L, Torregrosa MD et al. Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer. Lung Cancer 42(3), 345-354 (2003).
54. Rosell R, Scagliotti G, Danenberg KD et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22(23), 3548-3553 (2003).
55. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22(9), 1589-1597 (2004).